Heidelberg Pharma AG (HPHA.F)

2,9500 0,0000 (0,00%) Ab 09:17AM CEST. Markt geöffnet.

Heidelberg Pharma AG

Gregor-Mendel-Strasse 22
Ladenburg 68526
Germany
49 6203 1009 0
https://heidelberg-pharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 98

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Prof. Andreas Pahl	CEO & Spokesman of the Executive Board	328,28k	N/A	N/A
Mr. Walter Miller	Chief Financial Officer	N/A	N/A	N/A
Dr. Jorg Kemkowski	Chief Operating Officer	N/A	N/A	N/A
Sylvia Wimmer	Director Corporate Communication	N/A	N/A	N/A
Dr. Andras Strassz	Chief Medical Officer	N/A	N/A	N/A
Dr. George Octavian Badescu	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; and triple-negative breast cancer. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Corporate Governance

Heidelberg Pharma AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.